- Home
- AVK vs RIGL Comparison
AVK vs RIGL Comparison
Compare AVK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- RIGL
- Stock Information
- Founded
- AVK 2003
- RIGL 1996
- Country
- AVK United States
- RIGL United States
- Employees
- AVK N/A
- RIGL N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AVK Finance
- RIGL Health Care
- Exchange
- AVK Nasdaq
- RIGL Nasdaq
- Market Cap
- AVK 434.9M
- RIGL 486.4M
- IPO Year
- AVK N/A
- RIGL 2000
- Fundamental
- Price
- AVK $11.96
- RIGL $17.91
- Analyst Decision
- AVK
- RIGL Buy
- Analyst Count
- AVK 0
- RIGL 5
- Target Price
- AVK N/A
- RIGL $34.80
- AVG Volume (30 Days)
- AVK 112.9K
- RIGL 189.8K
- Earning Date
- AVK 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- AVK 11.85%
- RIGL N/A
- EPS Growth
- AVK N/A
- RIGL N/A
- EPS
- AVK N/A
- RIGL 0.22
- Revenue
- AVK N/A
- RIGL $157,374,000.00
- Revenue This Year
- AVK N/A
- RIGL $48.98
- Revenue Next Year
- AVK N/A
- RIGL $14.43
- P/E Ratio
- AVK N/A
- RIGL $83.48
- Revenue Growth
- AVK N/A
- RIGL 21.65
- 52 Week Low
- AVK $9.24
- RIGL $7.48
- 52 Week High
- AVK $12.16
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AVK 47.28
- RIGL 34.75
- Support Level
- AVK $12.00
- RIGL $18.34
- Resistance Level
- AVK $12.39
- RIGL $19.80
- Average True Range (ATR)
- AVK 0.12
- RIGL 1.58
- MACD
- AVK -0.04
- RIGL -1.11
- Stochastic Oscillator
- AVK 6.00
- RIGL 1.88
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.